Skip to content
Login
Search:
CROI Conference
CROI ConferenceCROI Conference
  • About CROI
    • CROI 2027 Important Dates
    • CROI Foundation
    • Scientific Program Committee and Community Liaison Subcommittee
    • Funding and Grant Support
    • IAS-USA
    • Policies, Website, and Copyrights
    • Illustrations of HIV, HCV, and SARS-CoV-2 Viruses
    • Contact Us
  • Abstracts
    • CROI Abstract Categories
    • Abstract Guidelines and Submission
    • Assignment of Abstract Copyright to CROI
    • People-First Language and the Use of Appropriate Terminology
  • Presenters
    • Invited Presenters and Moderators
    • Letter Of Invitation (For Visa And Other Purposes)
  • Attendees
    • Who Can Attend
    • Letter Of Invitation (For Visa And Other Purposes)
    • Affiliated and Proximate Activities
    • Frequently Asked Questions
  • Scholarships
    • New Researcher Scholarship
    • International Researcher Scholarship
    • Community Educator and Mentor Scholarships
  • Program
    • CROI 2027 Program
    • Our Voices
    • Media
    • Embargo Policies And Press Release Policies
    • Resources From Prior Years
    • Webcasts
    • Abstracts and ePoster Archive
    • CROI Issues of TAM
  • About CROI
    • CROI 2026 Preliminary Important Dates and Deadlines
    • CROI Foundation
    • Scientific Program Committee and Community Liaison Subcommittee
    • Funding and Grant Support
    • IAS-USA
    • Policies, Website, and Copyrights
    • Illustrations of HIV, HCV, and SARS-CoV-2 Viruses
    • Contact Us
  • Abstracts
    • Abstract Guidelines and Submission
    • CROI Abstract Categories
    • Assignment of Abstract Copyright to CROI
    • People-First Language and the Use of Appropriate Terminology
  • Presenters
    • Invited Presenters and Moderators
    • Oral Abstract Presentation Guidelines
    • Poster Presentation Guidelines
    • Themed Discussion Guidelines
    • Plain Language Summaries: A Mile-High View at CROI 2026
    • People-First Language and the Use of Appropriate Terminology
    • Letter Of Invitation (For Visa And Other Purposes)
  • Attendees
    • Registration
    • Who Can Attend
    • Media Accreditation and Registration
    • Affiliated and Proximate Activities
    • Frequently Asked Questions
  • Scholarships
    • New Researcher Scholarship
    • International Researcher Scholarship
    • Community Educator and Mentor Scholarships
    • Scholarship Travel
  • Program
    • CROI 2027 Program
    • CROI 2026 Resources
    • Our Voices
    • Media
    • Resources From Prior Years
    • Webcasts
    • Abstracts and ePoster Archive
    • CROI Issues of TAM
  • CROI 2027 Important Dates

Search Results for: node/PEP: Remember Me?

ANRS 174 DOXYVAC: AN OPEN-LABEL RANDOMIZED TRIAL TO PREVENT STIs IN MSM ON PrEP

By Jimmy He PharmD, DScMarch 24, 2023

…(Doxy PEP: 200 mg within 72h of condomless sex) or no PEP (2:1); and 2 shots of meningococcal B vaccine (Bexsero°) or no vaccine (1:1). Participants were tested centrally at…

Efficacy of Long-Acting Cabotegravir and Rilpivirine for PEP in a Macaque Model of RT SHIV Infection

By Jimmy He PharmD, DScMarch 6, 2024

…We examined whether a single injection of the combination of long-acting cabotegravir and rilpivirine (CAB LA and RPV LA) could be an effective PEP regimen in macaques. Methods: Human equivalent…

Impact of Doxycycline as STI PEP on the Gut Microbiome and Antimicrobial Resistance Gene Expression

By Jimmy He PharmD, DScMarch 6, 2024

Background: Doxycycline post-exposure prophylaxis (doxy-PEP) reduces bacterial sexually transmitted infections in men who have sex with men (MSM) and transwomen (TW) living with HIV or on HIV pre-exposure prophylaxis (PrEP)….

523 – Structural and Biochemical Characterization of a Novel Cyclic Peptide Targeting HIV-1 Capsid

By Jimmy He PharmD, DScApril 1, 2026

…complex with cyclic peptide (cyFG5) by X-ray crystallography. This structure was compared to reported WT unliganded, PF74-bound, and Nup153 peptide-bound structures (PDB: 4XFX, 4XFZ, 6AYA). Site-directed mutagenesis was performed on…

HIGH-RESOLUTION MAPPING OF T-CELL IMMUNITY TO THE ENTIRE SARS-CoV-2 PROTEOME

By Jimmy He PharmD, DScApril 22, 2021

…CoV-2 proteome. We synthetized a 15-mer peptide library of 2790 peptides (11 amino acid overlap) covering a CoV-2cons proteome sequence based on 1700 sequences. We designed a mega matrix of…

Young CPHIV Have Low Proinsulin to C-Peptide Ratios That Inversely Correlate With T-Cell Exhaustion

By Jimmy He PharmD, DScMarch 6, 2024

Background: Persons with HIV have an increased risk of developing diabetes mellitus. The ratio of immature (Pro-insulin) relative to mature (C-peptide) insulin products (PI:C) in circulation serves as a biomarker…

Adherence Markers for Doxy-PEP in Plasma and Urine

By Jimmy He PharmD, DScMarch 6, 2024

Background: Clinical trials of Doxy-PEP demonstrated high efficacy in preventing bacterial sexually transmitted infections (STIs) among men who have sex with men but not in women. Low Doxy-PEP efficacy observed…

HYPERTENSION SCREENING AND MANAGEMENT IN TWO PEPFAR-FUNDED CLINICS IN MALAWI

By Enthusiast Inc MDMarch 6, 2018

…enhanced an electronic medical record system by developing a HTN module to monitor this subpopulation for outcomes of interest. Antiretroviral (ART) adherence was measured using pill counts. From 2/15 to…

Early Adopters and Incident PrEP Prescribing in a Detailing Campaign, 2014-2015

By Enthusiast Inc MDFebruary 16, 2016

…estimating equations. Adjusted odds ratios (aOR) and 95% confidence intervals (CI) were reported with all characteristics adjusted for each other except PEP; PEP was adjusted for all others. At initial…

49 – Leveraging Private-Sector Pharmacies to Expand Reach of Biomedical HIV Prevention Interventions

By Jimmy He PharmD, DScMarch 18, 2025

…underrepresented in clinic-based PrEP/PEP programs (e.g., men, unmarried individuals) and is highly acceptable and feasible to pharmacy clients and providers. Implementation challenges, however, include heavy burden on provider time (particularly…

←1
2345678
…910111213…
141516171819202122232425262728293031323334353637383940414243444546474849505152535455565758596061626364656667686970717273747576777879808182
83→
Copyright © 2026 CROI Foundation/IAS-USA. All Rights Reserved.
Website by Enthusiast, Inc.
  • About CROI
  • Presenters
  • Abstracts
  • Scholarships
  • Program
Footer Menu
Go to Top